| Mirdametinib studied in …STUDIED_INderived21 of 21show fewer |
|---|
| → studied in | NCT06876142Phase 1/Phase 2 · suspended Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma · 21 trials list this drug (9 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06843967Phase 1/Phase 2 · recruiting A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma · 21 trials list this drug (9 active) | — | — | Liposarcoma,Round Cell Liposarcoma,Dedifferentiated Liposarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923126Phase 1/Phase 2 · recruiting SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma · 21 trials list this drug (9 active) | — | — | Low Grade Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061951Phase 2 · recruiting Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia · 21 trials list this drug (9 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07539441Phase 1/Phase 2 · recruiting A Study of Mirdametinib in People With Central Nervous System Tumors · 21 trials list this drug (9 active) | — | — | Central Nervous System Neoplasm,Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05580770Phase 1/Phase 2 · terminated Mirdametinib + BGB-3245 in Advanced Solid Tumors · 21 trials list this drug (9 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06666348Phase 1/Phase 2 · recruiting Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK · 21 trials list this drug (9 active) | — | — | Childhood Low Grade Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05028166available Individual Patient Compassionate Use of Mirdametinib · 21 trials list this drug (9 active) | — | — | Histiocytic and Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983159Phase 2 · recruiting A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations · 21 trials list this drug (9 active) | — | — | Lymphangioma,Venous Hemangioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06159166Phase 1/Phase 2 · recruiting Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). · 21 trials list this drug (9 active) | — | — | Skin Neurofibroma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07521657Phase 2 · not yet recruiting Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma · 21 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03905148Phase 1 · completed Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors · 21 trials list this drug (9 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07237100Phase 2 · recruiting Mirdametinib in Patients With Advanced NF1-mutant Melanoma · 21 trials list this drug (9 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02039336Phase 1/Phase 2 · completed Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC · 21 trials list this drug (9 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05054374Phase 1/Phase 2 · completed A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer · 21 trials list this drug (9 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Solid Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02022982Phase 1 · completed PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors · 21 trials list this drug (9 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02510001Phase 1 · completed MEK and MET Inhibition in Colorectal Cancer · 21 trials list this drug (9 active) | — | — | Solid Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02096471Phase 2 · completed MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 · 21 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01347866Phase 1 · terminated Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer · 21 trials list this drug (9 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00147550Phase 1/Phase 2 · terminated MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. · 21 trials list this drug (9 active) | — | — | Breast Neoplasm,Melanoma,Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00174369Phase 2 · terminated MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer · 21 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |